Abstract
Purpose of Review
Over the past 10 years, there has been a dramatic increase in basic and clinical research involving functional gastrointestinal disorders (FGIDs). New diagnostic and biomarker procedures are helping to identify physiologic disruptions associated with FGIDs on cellular and molecular levels. Simultaneously, clinicians are using new approaches to help manage patients with FGIDs. Among these, an important component of care has been the use of medical foods. These include probiotics, prebiotics, synbiotics, peppermint oil, caraway oil, curcumin, bovine immunoglobulin and many others.
Recent Findings
The putative effects of different medical foods make these therapies attractive for the management of FGIDs. These include effects on several pathophysiological mechanisms such as anti-inflammatory, smooth muscle relaxation, analgesia, mitigation of gut barrier dysfunction, and stimulation or inhibition of gastrointestinal receptors. Recent research has also demonstrated the efficacy of medical food products such as peppermint oil and serum-derived bovine immunoglobulin for the management of irritable bowel syndrome. Older data supports the probiotic VSL#3 and Bifidobacterium species. For functional dyspepsia, positive effects have been observed with the combination of caraway seed oil and peppermint oil as well as with STW-5, a botanical combination preparation, although robust RCTs are lacking.
Summary
With advancing knowledge regarding the pathogenesis of FGIDs, it is likely that the compounds available in the medical food category will increase dramatically, and they could play an important role in the management of several common and bothersome gastrointestinal conditions in the future.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Weng W, Chen J. The eastern perspective on functional foods based on traditional Chinese medicine. Nutr Rev. 1996;54:S11–6.
Kamboj V. Herbal medicine. Curr Sci. 2000;78:35–9.
Zhou S, Zhang S, Shen H, Chen W, Xu H, Chen X, et al. Curcumin inhibits cancer progression through regulating expression of microRNAs. Tumor Biol. 2017;39:1–12.
Jiang S, Han J, Li T, Xin Z, Ma Z, Di W, et al. Curcumin as a potential protective compound against cardiac diseases. Pharmacol Res. 2017;119:373–83.
Pavan AR, Silva GD, Jornada DH, Chiba DE, Fernandes DF, Man Chin C, et al. Unraveling the anticancer effect of curcumin and resveratrol. Nutrients. 2016;8(11):628. https://doi.org/10.3390/nu8110628
Yang CS, Jin H, Guan F, Chen YK, Wang H. Cancer preventive activities of tea polyphenols. Molecules. 2016;21:1–19.
Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, et al. Targeting mitochondria with avocatin B induces selective leukemia cell death. Cancer Res. 2015;75:2478–88.
•• Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262–79. Updated clinical criteria and evidence review of the various functional gastrointestinal disorders. Key reading for a fuller understanding of the current approach to the diagnosis and management of these disorders.
Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil. 2008;20(s1):121–9.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–21.
Mahadeva S, Ford AC. Clinical and epidemiological differences in functional dyspepsia between the East and the West. Neurogastroenterol Motil. 2016;28:167–74.
•• Burnett BP, Levy RM. Proposed industry nest practices in development and marketing of medical foods for the management of chronic conditions and diseases while awaiting regulation. Food Drug Law J. 2017;72:53–77. Excellent position paper on the current landscape of regulatory issues surrounding medical foods and the history of this class of therapies.
5(b)(3) of the Orphan Drug Act (21 U.S.C. 360ee(b)(3)). https://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/OrphanDrugAct/default.htm. Retrieved 28 Jan 2017.
U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition. Frequently asked questions about medical foods. Guidance for industry. 2nd ed. May 2016.
De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.
Aitken M, Kleinrock M, Lyle J Nass D, Caskey L. Medicines use and spending shifts: a review of the use of medicines in the US in 2014. IMS Inst Healthc Inf. 2015. http://www.imshealth.com/en/thought-leadership/ims-institute/reports/medicines-use-in-the-us-2014.
Linnaeus C. Species Plantarum. Stockholm. 2:1762–3.
Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2:101–18.
Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther. 2003;17:445–51.
Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. J Clin Pharm Ther. 1977;2:171–7.
Galeotti N, Di Cesare ML, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neurosci Lett. 2002;322:145–8.
Hawrelak JA, Cattley T, Myers SP. Essential oils in the treatment of intestinal dysbiosis: a preliminary in vitro study. Altern Med Rev. 2009;14:380–4.
Juergens UR, Stober M, Vetter H. The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. Eur J Med Res. 1998;3:539–45.
Walstab J, Wohlfarth C, Hovius R, Schmitteckert S, Roth R, Lasitschka F, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil. 2014;26:810–20.
Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–12.
•• Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016;61:560–71. Important randomized controlled trial evaluating peppermint oil for IBS demonstrating improvements in multiple and global symptoms vs placebo.
Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013;6:49–60.
Valentin N, Camilleri M, Carlson P, Harrington SC, Eckert D, O’Neill J, et al. Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. Physiol Rep. 2017;5(5):e13170.
Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome of functional diarrhea. Res Microbiol. 2001;152:735–41.
Kim HJ, Camilleri M, McKinzie S, et al. A randomized control trial of a probiotic, VSL #3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895–904.
Kim HJ, Roque MI, Camilleri M, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic combination VSL #3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–96.
Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL #3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gatrointest Liver Physiol. 2009;296(5):G1140–9.
Michail S, Kenche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL #3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins. 2011;3(1):1–7.
Wong RK, Yang C, Song GH, Wong J, Ho KY. Melatonin regulation as a possible mechanism for probiotic (VSL #3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015;60:186–94.
Walker MM, Alasdair W, Ung C, Talley NJ. The role of eosinophils and mast cells in intestinal functional disease. Curr Gastroenterol Rep. 2011;13:323–30.
Talley NJ, Fodor AA. Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little? Gastroenterology. 2011;141:1555–9.
Hod K, Ringel Y. Probiotics in functional bowel disorders. Best Pract Res Clin Gastroenterol. 2016;30(1):89–97.
Curro D, Ianiro G, Pecere S, Bibbò S, Cammarota G, et al. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol. 2016;174(11):1426–49.
May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther. 2000;14:1671–7.
Coon TJ, Ernest E. Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther. 2002;16:1689–99.
Shams R, Oldfield EC, Copare J, Johnson DA. Peppermint oil: clinical uses in the treatment of gastrointestinal diseases. JSM Gastroenterol Hepatol. 2015;3(1):1035–46.
Chey WD, Lacy BE, Cash BD, Epstein M, Shah S. Efficacy of caraway oil/l-menthol plus usual care vs placebo plus usual care, in functional dyspepsia patients with post-prandial distress (PDS) or epigastric pain (EPS) syndromes: results from a US RCT. Gastroenterology. 2017;152(5):S307.
Cremonini F. Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials. Neurogastroenterol Motil. 2014;26:893–900.
Sibaev A, Yuece B, Kelber O, Weiser D, Schirra J, Goke B, et al. STW5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. Phytomedicine. 2006;13(Suppl 5):80–9.
•• von Arnim U, Peitz U, Vinson B, Gindermann KJ, Malfertheiner P. STW5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102:1268–75. Large randomized controlled trial demonstrating efficacy for FD with STW-5 over 6 months compared to placebo.
Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast)—a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163:65–72.
Braden B, Caspary W, Borner N, Vinson B, Schneider AR. Clinical effects of STW5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009;21(6):632–8.
Madisch A, Holtmann G, Plein K, Holtz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicenter trial. Aliment Pharmacol Ther. 2004;19:271–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Brent Acker declares no conflict of interest. Brooks Cash reports receiving personal fees from IM Health Sciences.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Neurogastrointerology and Motility Disorders of the Gastrointestinal Tract
Rights and permissions
About this article
Cite this article
Acker, B.W., Cash, B.D. Medicinal Foods for Functional GI Disorders. Curr Gastroenterol Rep 19, 62 (2017). https://doi.org/10.1007/s11894-017-0601-x
Published:
DOI: https://doi.org/10.1007/s11894-017-0601-x